FRIDAY, Oct. 6, 2023 — The first-in-class novel human immunoglobulin G1 Fc fragment, efgartigimod, is efficacious and safe for patients with chronic or persistent primary immune thrombocytopenia, according to a study published online Sept. 28 in…Original Article
Efgartigimod Efficacious, Safe for Primary Immune Thrombocytopenia
FRIDAY, Oct. 6, 2023 — The first-in-class novel human immunoglobulin G1 Fc fragment, efgartigimod, is efficacious and safe for patients with chronic or persistent primary immune thrombocytopenia, according to a study published online Sept. 28 in…
